Oryzon to invest eur 20 million to develop new drugs
Catalan Economy
10 Sep 2009
Biotech company oryzon genomics has announced a four-year program to invest eur 20 million in the development of new drugs. oryzon ceo carlos buesa indicated that the company would use the resources to strengthen its research on biomarkers and antibody therapy.
oryzon recently opened its new 2,300-square-meter corporate headquarters in cornellà de llobregat (barcelona), with an investment of eur 2.5 million. the company expects revenue of eur 8 million for its current fiscal year.
source: expansión catalunya, 08/09/09
Related News and Success stories.
-
29 Jul 2024
Catalonia joins ELLIS, the European network of excellence in research and innovation on Artificial Intelligence
-
19 Jul 2024
Catalonia's nautical sector generates over €1 billion and creates 4,000 jobs
-
17 Jul 2024
Discover Catalonia’s 10 most disruptive companies of 2024
-
11 Jul 2024
Catalonia leads a €23 million European project for personalized medicine and advanced therapies